Valeo Financial Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Valeo Financial Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-45	Closed	-$6K	–	562
2021 Q1	$6K	Sell	45 -2	-4%	-$301	﹤0.01%	1488
2020 Q4	$6K	Hold	47	–	–	﹤0.01%	1310
2020 Q3	$7K	Sell	47 -66	-58%	-$9.38K	﹤0.01%	1156
2020 Q2	$17K	Hold	113	–	–	﹤0.01%	1109
2020 Q1	$13K	Buy	113 +64	+131%	+$7.39K	﹤0.01%	991
2019 Q4	$6K	Hold	49	–	–	﹤0.01%	1217
2019 Q3	$4K	Hold	49	–	–	﹤0.01%	1223
2019 Q2	$4K	Sell	49 -7	-13%	-$537	﹤0.01%	1239
2019 Q1	$5K	Hold	56	–	–	﹤0.01%	1136
2018 Q4	$4K	Hold	56	–	–	﹤0.01%	1116
2018 Q3	$4K	Buy	56 +5	+10%	+$503	﹤0.01%	1247
2018 Q2	$5K	Hold	51	–	–	﹤0.01%	1114
2018 Q1	$6K	Hold	51	–	–	﹤0.01%	1061
2017 Q4	$6K	Hold	51	–	–	﹤0.01%	948
2017 Q3	$6K	Buy	+51	New	+$4.35K	﹤0.01%	813

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Valeo Financial Advisors's ALNY Position: Q2 2021 in Review

Valeo Financial Advisors sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2021, closing a stake of 45 shares — an estimated $6K sold.

Valeo Financial Advisors first reported a position in ALNY in Q3 2017 and held it in 15 quarters. The position peaked at $17K in Q2 2020. 401 funds tracked by Wall St. Rank hold ALNY as of Q2 2021.

Valeo Financial Advisors reported no remaining Alnylam Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
Valeo Financial Advisors sold 45 Alnylam Pharmaceuticals shares in Q2 2021, an estimated $6K.
Valeo Financial Advisors first reported a position in Alnylam Pharmaceuticals in Q3 2017 and held it in 15 quarters.
Valeo Financial Advisors's Alnylam Pharmaceuticals position peaked at $17K in Q2 2020.
401 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2021.

Based on Valeo Financial Advisors's 13F filing for Q2 2021, filed 22 Jul 2021.